Clinical efficacy of blastocyst culture supernatant transfer in hormone replacement frozen-thawed embryo transfer cycle: a prospective double-blind randomized controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055408

Enrollment

Unknown

Registered

2022-01-08

Start date

2017-09-16

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female infertility

Interventions

experimental group:blastocyst culture supernatant transfer

control group:conventional culture medium transfer

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. The first frozen embryo transfer; 2. Aged 20-40 years; 3. Basic endocrine FSH= 7mm and progesterone <= 1.0ng/ml on the day of secretory transformation.

Exclusion criteria

Exclusion criteria: 1. Uterine abnormal diseases, including uterine malformations (unicornuate uterus, bicornuate uterus, septate uterus, double uterus), adenomyosis, submucosal fibroids, intrauterine adhesions, etc.; 2. Hydrosalpinx; 3. 2 or more spontaneous abortions; 4. Both spouses have chromosomal abnormalities; 5. Taking drugs or treatments that affect reproductive and metabolic functions, including diabetes drugs, some antihypertensive drugs (diazoxide, ACEI inhibitors, calcium channel blockers), Chinese herbal medicine, acupuncture.

Design outcomes

Primary

Measure	Time frame
Live birth rate;	—

Secondary

Measure	Time frame
Clinical pregnancy rate;Early abortion rate;	—

Countries

China

Contacts

Public ContactDong Xi

dong.xi@zs-hospital.sh.cn+86 13601760718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026